Archive | Drugs RSS feed for this section
Yaz associated with a higher risk for blood clots
FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills.Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. BACKGROUND: Drospirenone is a synthetic version of [...]
Continue reading...Qnexa Diet drug rejected by FDA to be reviewed again
17. February 2012
The F.D.A. rejected Qnexa in 2010, amid safety concerns, and the drug’s manufacturer is now presenting additional data to argue its case. But thousands of people in central California, where Qnexa’s inventor ran a weight-loss clinic, and others across the country have not had to wait for the drug’s approval. Through a regulatory loophole of [...]
Continue reading...Pradaxa Lawsuit
13. February 2012
Pradaxa (dabigatran etexilate mesylate) is a new blood thinning drug manufactured by Boehringer Ingelheim Pharmaceuticals. Pradaxa is in a class of drugs called Direct Thrombin Inhibitors, otherwise known as anticoagulants or blood thinners. Pradaxa was approved by the FDA in October of 2010 as a blood thinner that was superior to Warfarin because it allegedly [...]
Continue reading...Adcetris brain infection death
13. January 2012
FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin). Due to the serious nature of PML, a new Boxed Warning highlighting this risk has been added to the drug label. [...]
Continue reading...Statin cholesterol-lowering drugs linked to Type 2 diabetes
10. January 2012
A new side effect seems to be emerging for those cholesterol-lowering wonder drugs called statins: They may increase some people’s chances of developing Type 2 diabetes. The best-selling statin is atorvastatin, marketed as Lipitor and Torvast. A number of statins are on the market: atorvastatin (Lipitor and Torvast), fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin [...]
Continue reading...Bladder Cancer in Actos users
9. January 2012
Diabetes drug Actos has been linked to high risk of bladder cancer and other injuries. Recent medical studies confirm that Actos can cause bladder cancer and other injuries. Actos (pioglitazone) is a Type 2 diabetes drug often prescribed as an alternative to Avandia. At one time it was believed that Actos was safer. Actos lawsuits against Takeda [...]
Continue reading...FDA warning on Multaq and Increased Risk of Death
22. December 2011
U.S. Food and Drug Administration has completed a safety review of Multaq (generic name dronedarone). According to this review, in patients with permanent atrial fibrillation (AF), Multaq increased the risk of serious cardiovascular events, including death. The data was obtained from ATHENA and PALLAS clinical trials. New information and recommendations are being provided by FDA for [...]
Continue reading...Actos Active Ingredient
17. November 2011
Actos is a Type 2 diabetes drug which has been linked to an increased risk of heart attack, congestive heart failure, heart disease and death. It has also been linked to an increased risk of bladder cancer, rhabdomyolysis (kidney damage), liver damage, and bone fracture. Here is an updated list of drugs with active ingredient [...]
Continue reading...Actos Bladder Cancer Lawsuit
3. November 2011
The Diabetes drug Actos has been linked to high risk of bladder cancer and other injuries. Common Symptops: Dark urine Frequent urination Painful urination Urinary tract infection Drugs effected Generic name: Pioglitazone Actos ACTOplus met ACTOplus met XR duetact NDC numbers found on Actos packaging: 00247-1924-30 00247-1925-30 00247-1926-30 12280-0060-30 13411-0101-03 13411-0102-03 13411-0103-03 21695-0147-15 21695-0148-15 49999-0450-30 49999-0451-30 54569-4880-00 [...]
Continue reading...Infant heart defect risks increase with SSRIs
11. August 2011
Pregnant women who take selective serotonin reuptake inhibitors (SSRIs) may be putting their babies at risk for heart defects. SSRIs, which are normally used to treat obsessive-compulsive disorders, anxiety disorders, and depression, have also been linked to heart defects in infants. The risk appears greatest when pregnant women take the drugs in the later part [...]
Continue reading...
- Risperdal (Resperidone)
- FDA issues warning on Advair, Symbicort, Foradil and Serevent
- Benzoyl Peroxide Acne Cream 10% Contained Burkholderia Cepacia Bacteria
- Crestor Linked to Rhabdomyolysis (Fatal Muscle Disease)
- Merck’s Vioxx $4.85 billion payouts to begin in August
- Zoloft lawsuit
- Infants' Mylicon Gas Relief Dye Free Drops Recalled
- Fluoroquinolone Antimicrobial Drugs
- Arthritis Drug Vioxx Recalled
- Tysabri monotherapy and progressive multifocal leukoencephalopathy
- None found
- Yaz associated with a higher risk for blood clots
- FDA Issues warning on counterfeit Avastin
- Pfizer birth control pills may not prevent pregnancy
- Adcetris brain infection death
- FDA warning on Multaq and Increased Risk of Death
- SSRI and Potential Risk of Persistent Pulmonary Hypertension
- Serious Complications Associated with Vaginal Mesh devices
- Actos Lawsuit
- Infant heart defect risks increase with SSRIs
- Birth defects more likely with SSRI use
10. April 2012
0 Comments